Healthcare & Biotech Stocks Just Hit Brand New 2019 Highs
Over the course of the past decade or so, the biotech sector has emerged as one of the most important ones for investors of all hues. It is not a surprise that many experts recommend that investors should allocate some money towards biotech stocks.
Although it is true that the sector is growing rapidly, one needs to do research well in order to discover the best possible stocks. One way of doing that is by watching the market closely and keeping tabs on the latest news. Here is a look at 3 biotech stocks that could be in the watch lists of investors before 2020.
Sernova Corp’s (TSX:SVA) (OTC:SEOVF)
Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes
This was presented just a few months ago and could show exactly why Sernova (TSX:SVA) (OTC:SEOVF) has started generating more interest across the medical community and public market as well. Sernova (TSX:SVA) (OTC:SEOVF)’s Cell Pouch™ transplanted with islet cells showed initial safety, as well as key efficacy measures, including:
- Glucose stimulated C-peptide
- Insulin production
- Clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness.
There was specifically an 87.5% reduction in hypoglycemic events from baseline collected over a two-week monitoring period. These data were so strongly delivered that it has firmly warranted advancing its clinical trials to more patients with type-1 diabetes.
Sorrento Therapeutics Rejects Buyout Offer On Lower Valuation
The first biotech stock to put into the watch list is that of Sorrento Therapeutics Inc (NASDAQ:SRNE), which made a major announcement on Monday. The company announced that it has rejected an unsolicited buyout proposal. The proposals had been made by two pharma companies but Sorrento stated that the company the interested parties had undervalued the company to a large extent.
The company revealed that it would have been an all-cash deal. It offered between $3 to $5 for the outstanding shares of Sorrento. The company currently holds a value of $227 million and the proposal had valued it at $709.4 million. Shares jumped by as much as 94.37% and closed at $3.11 in Monday’s trading session after the news broke.
Aquestive Therapeutics Gets the FDA Approval
The other biotech stock that has made impressive gains on Monday is that of Aquestive Therapeutics Inc (NASDAQ:AQST), which jumped by as much as 17.26% after one of its products received approval by the Food and Drug Administration this past Friday.
The Exservan Oral Film treats amyotrophic lateral sclerosis and currently, around 30,000 people in the United States suffer from the condition. The jump in the stock is perfectly understandable. However, note that the Aquestive stock has been on a roll over the past month and has gained as much as 138% during the period.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 11, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.
2 Biotech Stocks To Watch Before Next Week
Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.
Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.
Biotech Stocks To Watch: Marinus Pharmaceuticals
The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS) which has made significant gains on Wednesday on the back of an important announcement.
On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.
Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.
Biotech Stocks To Watch: Diffusion Pharmaceuticals
The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.
It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.
StockPrice.com Subscribers WIN BIG!
We owe you a BIG congratulations. The whole point of StockPrice.com is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.
Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).
Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!
Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report
This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?
STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam
STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time
Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE
Are These Biotech Stocks To Buy Or Sell Right Now?
2 Biotech Stocks Rally But Can That Continue?
One of the sectors that have proven to be a consistently steady performer in the stock market over the past few years is the biotech sector. Hence, it is not really a surprise that investors are almost always on the lookout for the next big thing among biotech stocks.
However, it is important to note that even though biotech is a prosperous sector, an investor needs to put in his fair share of research in order to discover potential winners. Here is a look at two biotech stocks that could be tracked by investors closely over the coming days.
Vistagen Therapeutics Gains As FDA Grants fast track designation for PH94B
The first one to consider is that Vistagen Therapeutics Inc (VTGN Stock Report) that made significant gains after the company made a major announcement with regards to one of its products. The company announced on Tuesday that its social anxiety disorder product PH94B has been granted fast track designation by the United States Food and Drug Administration.
As everyone knows, it is a significant milestone for the company as it tries to bring the product to the market and the market naturally reacted positively to the news. The stock shot up by as much as 44.60% on the back of the news and has emerged as one of the biotech stocks that could be tracked closely today.
Iterum Therapeutics up 280% in 3 Weeks
The other biotech stock that has made a significant move this morning is that of Iterum Therapeutics PLC (NASDAQ:ITRM). On Tuesday, the stock rallied by as much as 22% but there was no material news with regards to the company that could have triggered that sort of a rally. However, last month, the company had made a major announcement about one of its products.
Iterum announced that it had completed enrolment of patients for the study of Sulopenem for Resistant Enterobacteriaceae (SURE). The medicine meant for treating complicated urinary tract infections. The stock has rallied by as much as 270% since the news broke back on November 18.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology1 week ago
3 Pharma Stocks To Watch In December 2019
Entertainment2 weeks ago
Is It Time To Buy Or Sell Netflix; Streaming Wars Heat Up
Entertainment2 weeks ago
Disney (DIS) Streaming Business is Getting 1 Million Subscribers a Day
Featured2 weeks ago
Stock Price Black Friday Newsletter – November 29, 2019
Featured2 weeks ago
Stock Price Monday Morning Update – December 2, 2019
Newsletter1 week ago
Stock Price Thursday Morning Update – December 5, 2019
Featured7 days ago
Stock Price Newsletter – December 6, 2019
Featured1 week ago
Stock Price Newsletter – December 3, 2019